When interest rates are low, capital is willing to go to riskier enterprises like biotech in order to get a larger return compared to the alternatives.
When interest rates are high, capital shifts to yield-generating, interest-bearing investments. They give higher returns with less risk.
So basically the ROI of biotech becomes less competitive compared to alternatives. You have the same number of people/firms chasing a smaller supply of investment dollars.